Niagen Bioscience Establishes First-Ever USP Monograph for Patented Nicotinamide Riboside Chloride

The new quality benchmark reinforces the company's leadership in NAD+ science and ingredient quality.

Apr. 9, 2026 at 5:36pm

Got story updates? Submit your updates here. ›

A bold, abstract painting in earthy tones of green, brown, and blue, featuring sweeping geometric arcs, concentric circles, and precise botanical spirals, conceptually representing the complex molecular structure and scientific significance of nicotinamide riboside chloride (NRCl).The establishment of a USP monograph for Niagen Bioscience's patented NRCl ingredient represents a significant milestone in the NAD+ supplement industry, providing a clear quality standard that will benefit consumers.Los Angeles Today

Niagen Bioscience, a leading biotech company, has collaborated with the United States Pharmacopeia (USP) to establish the first-ever USP monograph for Nicotinamide Riboside Chloride (NRCl), the patented form of the ingredient used in Niagen supplements. This milestone represents the first pharmacopeial quality benchmark for NR, NMN, and NAD+ compounds, further solidifying Niagen Bioscience's position as an innovator in the NAD+ science field.

Why it matters

The establishment of a USP monograph for NRCl is a significant achievement that provides a clear quality standard for this important NAD+ precursor compound. As the use of NAD+ boosting supplements continues to grow, this monograph will help ensure consistency and quality across the industry, benefiting consumers and reinforcing Niagen Bioscience's leadership in this space.

The details

The monograph for NRCl was developed based on the scientific data, analytical methods, and specifications that Niagen Bioscience had previously established for its patented Niagen ingredient. This rigorous process ensures that the USP monograph reflects the high-quality standards that Niagen Bioscience has maintained for its products.

  • Niagen Bioscience collaborated with USP to establish the NRCl monograph in 2026.

The players

Niagen Bioscience, Inc.

A leading biotech company focused on NAD+ science and the development of high-quality supplements containing Nicotinamide Riboside Chloride (NRCl).

United States Pharmacopeia (USP)

An independent, scientific, non-profit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements.

Got photos? Submit your photos here. ›

The takeaway

The establishment of a USP monograph for Niagen Bioscience's patented NRCl ingredient represents a significant milestone in the NAD+ supplement industry, providing a clear quality standard that will benefit consumers and reinforce the company's leadership in this growing market.